PL2512515T3 - Kompozycja farmaceutyczna do leczenia zespołu suchego oka - Google Patents

Kompozycja farmaceutyczna do leczenia zespołu suchego oka

Info

Publication number
PL2512515T3
PL2512515T3 PL10790775T PL10790775T PL2512515T3 PL 2512515 T3 PL2512515 T3 PL 2512515T3 PL 10790775 T PL10790775 T PL 10790775T PL 10790775 T PL10790775 T PL 10790775T PL 2512515 T3 PL2512515 T3 PL 2512515T3
Authority
PL
Poland
Prior art keywords
treatment
pharmaceutical composition
dry eye
eye syndrome
syndrome
Prior art date
Application number
PL10790775T
Other languages
English (en)
Inventor
Bastian Theisinger
Sonja Theisinger
Bernhard Günther
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2512515(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of PL2512515T3 publication Critical patent/PL2512515T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10790775T 2009-12-14 2010-12-13 Kompozycja farmaceutyczna do leczenia zespołu suchego oka PL2512515T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09015423A EP2335735A1 (en) 2009-12-14 2009-12-14 Pharmaceutical composition for treatment of dry eye syndrome
PCT/EP2010/069495 WO2011073134A1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome
EP10790775.0A EP2512515B1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome

Publications (1)

Publication Number Publication Date
PL2512515T3 true PL2512515T3 (pl) 2014-05-30

Family

ID=41731659

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10790775T PL2512515T3 (pl) 2009-12-14 2010-12-13 Kompozycja farmaceutyczna do leczenia zespołu suchego oka

Country Status (15)

Country Link
US (1) US8614178B2 (pl)
EP (2) EP2335735A1 (pl)
JP (5) JP5663595B2 (pl)
KR (2) KR101652714B1 (pl)
CN (1) CN102652022B (pl)
AU (1) AU2010333039B2 (pl)
BR (3) BR112012014190B8 (pl)
CA (2) CA2776860C (pl)
DK (1) DK2512515T3 (pl)
ES (1) ES2449308T3 (pl)
IN (1) IN2012DN03128A (pl)
MX (1) MX2012006720A (pl)
PL (1) PL2512515T3 (pl)
PT (1) PT2512515E (pl)
WO (1) WO2011073134A1 (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010256558B2 (en) 2009-06-03 2013-10-03 Forsight Labs, Llc Anterior segment drug delivery
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2714008T3 (en) 2011-05-25 2017-03-13 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
EP2708228B1 (en) 2012-09-12 2018-05-16 Novaliq GmbH Eye wash compositions
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
JP6304475B2 (ja) * 2013-01-31 2018-04-04 ロート製薬株式会社 点眼剤
CN105073112B (zh) 2013-03-13 2017-12-29 参天制药株式会社 睑板腺功能障碍的治疗剂
CN114028560A (zh) * 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
CA2927321A1 (en) * 2013-10-15 2015-04-23 Forsight Vision5, Inc. Formulations and methods for increasing or reducing mucus
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11013403B2 (en) * 2015-09-29 2021-05-25 The Regents Of The University Of California Methods of diagnosing diseases of mucosal surfaces
CN113662929A (zh) * 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
KR20190057338A (ko) * 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
BR112019006194A2 (pt) * 2016-09-28 2019-06-18 Novaliq Gmbh composições que compreendem um ligante de ligação ao receptor de canabinóides
WO2018114557A1 (en) * 2016-12-22 2018-06-28 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
ES2819005T3 (es) * 2016-12-23 2021-04-14 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
AU2018205253B2 (en) 2017-01-06 2022-01-13 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
EP3612228B1 (en) * 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
EP3619186B1 (en) 2017-05-05 2021-02-17 Novaliq GmbH Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
IL276888B2 (en) 2018-03-28 2024-12-01 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
KR20210080388A (ko) 2018-09-22 2021-06-30 노바리크 게엠베하 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
US20220008397A1 (en) * 2019-01-21 2022-01-13 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
AU2020281641B2 (en) 2019-05-24 2025-09-11 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
AU2020340561B2 (en) 2019-09-06 2026-01-22 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
WO2024170514A1 (en) * 2023-02-13 2024-08-22 Novaliq Gmbh Ophthalmic composition for ocular surgery preparation in patients with ocular surface disease
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
KR920003601B1 (ko) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19861012A1 (de) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
CN1190194C (zh) * 1999-04-30 2005-02-23 苏坎波公司 用于治疗干眼的大环内酯化合物的应用
DE19938668B4 (de) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
ES2387619T3 (es) * 2004-04-19 2012-09-27 Centre National De La Recherche Scientifique (Cnrs) Suplementos de tensioactivos pulmonares
JP2008501806A (ja) * 2004-06-08 2008-01-24 オキュラリス ファーマ, インコーポレイテッド 疎水性眼用組成物および使用方法
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
EP2110126B9 (de) 2008-04-18 2012-09-19 Novaliq GmbH Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich

Also Published As

Publication number Publication date
JP6731039B2 (ja) 2020-07-29
JP2017078086A (ja) 2017-04-27
EP2335735A1 (en) 2011-06-22
EP2512515B1 (en) 2013-12-25
CN102652022A (zh) 2012-08-29
HK1172269A1 (en) 2013-04-19
US20120244177A1 (en) 2012-09-27
JP2015028064A (ja) 2015-02-12
EP2512515A1 (en) 2012-10-24
BR122020020872B1 (pt) 2021-09-08
US8614178B2 (en) 2013-12-24
KR101722039B1 (ko) 2017-03-31
KR20160105533A (ko) 2016-09-06
BR112012014190A2 (pt) 2016-05-31
MX2012006720A (es) 2012-07-30
CN102652022B (zh) 2014-12-17
CA2776860C (en) 2016-10-25
BR122017018955B1 (pt) 2022-03-08
JP2013513586A (ja) 2013-04-22
PT2512515E (pt) 2014-03-04
CA2941956C (en) 2018-09-04
BR112012014190B8 (pt) 2021-05-25
CA2776860A1 (en) 2011-06-23
DK2512515T3 (en) 2014-03-10
CA2941956A1 (en) 2011-06-23
AU2010333039B2 (en) 2014-08-28
JP5663595B2 (ja) 2015-02-04
JP2019006803A (ja) 2019-01-17
IN2012DN03128A (pl) 2015-09-18
AU2010333039A1 (en) 2012-07-12
KR101652714B1 (ko) 2016-09-01
ES2449308T3 (es) 2014-03-19
JP2019070003A (ja) 2019-05-09
JP6397472B2 (ja) 2018-09-26
KR20120115977A (ko) 2012-10-19
WO2011073134A1 (en) 2011-06-23
JP6096731B2 (ja) 2017-03-15
BR112012014190B1 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
IL216800A (en) Preparation for the treatment of dry eye syndrome
PL2547323T3 (pl) Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
PT2482812T (pt) Composições farmacêuticas compreendendo bi-1356 e metformina
SI2415763T1 (sl) Farmacevtski sestavek za zdravljenje ali preprečevanje glavkoma
ZA201404121B (en) Compositions for the treatment of dry eye
PL2442799T5 (pl) Kompozycja farmaceutyczna w postaci stałej zawierająca rywaroksaban
PT2429507T (pt) Composição farmacêutica isenta de fosfatos para o tratamento do glaucoma
GB0902040D0 (en) Composition for treatment of skin
EP2213303A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
ZA201306905B (en) Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these
ZA201104670B (en) Pharmaceutical composition comprising aleglitazar
IL218726A0 (en) Methods and pharmaceutical compositions for treating down syndrome
EP2604264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRUS DISEASES
IL200753A (en) Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
EP2286810A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FIBROMYALGIA
ZA201204341B (en) Pharmaceutical composition for treating gutaneous burns
EP2402342A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
IL219050A0 (en) Pharmaceutical composition for the treatment of bladder disorders
PT2460509T (pt) Composição para tratamento de verrugas
IL215854A0 (en) Pharmaceutical compositions for the treatment of nasal polyposis
ZA201200531B (en) Pharmaceutical composition of rifampicin
HUP1100534A2 (en) Pharmaceutical composition for the treatment of muscle atrophy
EP2329824A4 (en) NEW PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NOZIZEPTIVE PAIN
GB0911577D0 (en) Compositions for the treatment of dry eye
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds